UroGen Pharma Ltd.

Princeton, NJ · Biotech · Public

Liposomes and specialized pharmaceutical delivery systems for urological therapies

Claim this profile

Follows are private to you and power your alerts

Updated · urogen.com

Sector
Biotech
Headquarters
Princeton, NJ
Latest Form D
$120M, Aug 2023
Total capital
$120M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$120M
1 Form D · last Aug 2023
38 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
12
24 pending · first 2017
Rank in peer group#141 of 1449

Capital timeline

2023FEDERAL ↑EQUITY ↓Cumulative $120M1st Form D$120M
2023FEDERAL ↑EQUITY ↓Cumulative $120M1st Form D$120M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$120M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#141 · top 10%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Arie Belldegrun, M.D.DirectorNamed in SEC Form D filings
  • Cynthia ButittaDirectorNamed in SEC Form D filings
  • Dan WildmanDirectorNamed in SEC Form D filings
  • Don KimExecutive OfficerNamed in SEC Form D filings
  • Elizabeth BarrettExecutive Officer, DirectorNamed in SEC Form D filings
  • Fred Cohen, M.D.DirectorNamed in SEC Form D filings
Show all 12 people
  • James A. Robinson, Jr.DirectorNamed in SEC Form D filings
  • Jason A. SmithExecutive OfficerNamed in SEC Form D filings
  • Leana Wen, M.D., MScDirectorNamed in SEC Form D filings
  • Mark A. Schoenberg, M.D.Executive OfficerNamed in SEC Form D filings
  • Ran NussbaumDirectorNamed in SEC Form D filings
  • Stuart Holden, M.D.DirectorNamed in SEC Form D filings

What it has protected

USPTO · 12 granted of 36
Show all 36 patent records
  • Treatment Of Low-grade Intermediate-risk Non-muscle-invasive Bladder Cancer With A Thermally Gelling Pharmaceutical Composition Containing MitomycinSep 22, 2026 · US 12,740,940Granted
  • Material And Method For Treating Internal CavitiesSep 10, 2026 · Application 19355114Pending
  • Material And Method For Treating Internal CavitiesOct 14, 2025 · US 12,440,568Granted
  • Immunomodulating Treatments Of Body CavitiesJul 10, 2025 · Application 19094915Pending
  • Material And Method For Treating CancerJun 24, 2025 · US 12,336,979Granted
  • Material And Method For Treating Internal CavitiesApr 8, 2025 · US 12,268,745Granted
  • Immunomodulating Treatments Of Body CavitiesApr 1, 2025 · US 12,263,245Granted
  • Treatment Of Low-grade Intermediate-risk Non-muscle-invasive Bladder Cancer With A Thermally Gelling Pharmaceutical Composition Containing MitomycinJan 30, 2025 · Application 18784354Pending
  • Material And Method For Treating CancerDec 24, 2024 · US 12,171,747Granted
  • Compositions Comprising A Thermoreversible Hydrogel, And Having An Extended In-use PeriodMar 28, 2024 · Application 18374645Pending
  • Material And Method For Treating Internal CavitiesAug 3, 2023 · Application 18129497Pending
  • Material And Method For Treating Internal CavitiesAug 3, 2023 · Application 18129508Pending
  • Material And Method For Treating Internal CavitiesJul 27, 2023 · Application 18129543Pending
  • Immunomodulating Treatments Of Body CavitiesJul 13, 2023 · Application 18180152Pending
  • Material And Method For Treating Internal CavitiesApr 21, 2022 · Application 17566882Pending
  • A Connectable CatheterMay 4, 2021 · US 10,994,109Granted
  • Immunomodulating Treatments Of Body CavitiesDec 24, 2020 · Application 17006926Pending
  • Pharmaceutical Compositions Comprising Imiquimod For Use In The Treatment Of Carcinoma In Situ Of The BladderSep 3, 2020 · Application 16593297Pending
  • Immunomodulating Treatments Of Body CavitiesSep 1, 2020 · US 10,758,482Granted
  • Material And Method For Treating Internal CavitiesApr 16, 2020 · Application 16518511Pending
  • Material And Method For Treating Internal CavitiesNov 12, 2019 · US 10,471,150Granted
  • Connectable Catheter SystemJan 3, 2019 · Application 16065923Pending
  • Material And Method For Treating Internal CavitiesAug 7, 2018 · US 10,039,832Granted
  • Material And Method For Treating Internal CavitiesApr 24, 2018 · US 9,950,069Granted
  • Pharmaceutical Compositions Comprising Imidazoquinolin(amines) And Derivatives Thereof Suitable For Local AdministrationSep 21, 2017 · Application 15608487Pending
  • Production Of Thermoreversible Hydrogels For Therapeutic ApplicationsMay 25, 2017 · Application 15427341Pending
  • Phospholipid Drug AnalogsJan 10, 2017 · US 9,540,407Granted
  • Pharmaceutical Compositions Comprising Imiquimod For Use In The Treatment Of Carcinoma In Situ Of The BladderNov 17, 2016 · Application 15110893Pending
  • Pharmaceutical Compositions Comprising Imidazoquinolin(amines) And Derivatives Thereof Suitable For Local AdministrationJan 14, 2016 · Application 14752358Pending
  • Device For Introducing Liquids Into The Urinary TractApplication 19623548Pending
  • Compositions Comprising A Thermoreversible Hydrogel, And Having An Extended In-use PeriodApplication 63411024Pending
  • Pharmaceutical Compositions Comprising Imiquimod For Use In The Treatment Of Carcinoma In Situ Of The BladderApplication 16276153Pending
  • Immunomodulating Treatments Of Body CavitiesApplication 63502418Pending
  • Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with a Reverse Thermal Gel Containing MitomycinApplication 63515352Pending
  • Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with a Reverse Thermal Gel Containing MitomycinApplication 63640252Pending
  • Material And Method For Treating Internal CavitiesApplication 63124111Pending
  • Star TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • NextPoint TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Quanta Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • ANAGINSimilar federal contract value in Biotech · null in contracts
  • Scipher Medicine CorpSimilar federal contract value in Biotech · null in contracts
  • Kumquat BiosciencesSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .